p14ARF deletion and methylation in genetic pathways to glioblastomas

Brain Pathology

Volumn 11, Issue 2, 2001, Pages 159-168

  Nakamura, Mitsutoshi ^a   Watanabe, Takao ^a   Klangby, Ulf ^b   Asker, Charlotte ^c   Wiman, Klas ^c   Yonekawa, Yasuhiro ^d   Kleihues, Paul ^a   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P14; UNCLASSIFIED DRUG; PROTEIN; PROTEIN P14ARF; PROTEIN P16INK4A;

ARTICLE; ASTROCYTOMA; CANCER SCREENING; CHROMOSOME 9P; DNA METHYLATION; GENE DELETION; GLIOBLASTOMA; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; BRAIN TUMOR; CHROMOSOME 9; CHROMOSOME MAP; GENETICS; HETEROZYGOSITY LOSS; METASTASIS; MUTATION; PATHOLOGY;

BRAIN NEOPLASMS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GENE DELETION; GENES, P16; GLIOBLASTOMA; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0034745338     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2001.tb00388.x     Document Type: Article

References (55)

1. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas
2. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
3. Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene
4. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas
5. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation
6. The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alterative beta trasncript of the p16INK4a/MTS1 gene
7. INK4a methylation and p53 mutational status
8. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas
9. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas
10. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
11. INK4a gene is frequently lost in small cell lung cancer
12. Splicing into senescence: The curious case of p16 and p19ARF
13. INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas
14. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
15. INK4a and the control of cellular proliferative life span
16. Germline p16 mutations in familial melanoma
17. 1-S transition control gene abnormalities
18. A common region of homozygous deletion in malignant human gliomas lies between the IFN alpha/omega gene cluster and the D9S171 locus
19. ARF, PTEN tumor suppressor genes in human glioma cell lines
20. Methylation, mutation and cancer
21. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
22. Tumor spectrum in ARF-deficient mice
23. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
24. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis
25. Primary and secondary glioblastomas: From concept to clinical diagnosis
26. ARF gene in metastatic melanoma cell lines
27. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors
28. Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus
29. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors
30. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer
31. Frequent alterations of cell-cycle regulators in astrocytic tumors as detected by molecular genetic and immunohistochemical analyses
32. Loss of heterozygosity on chromosome 19 in secondary glioblastomas
33. ARF gene deletion in high-grade adult and pediatric astrocytomas
34. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence
35. Art, interacts with MDM2 and neutralizes MDM2's inhibition of p53
36. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
37. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer
38. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours
39. Role of the INK4a locus in tumor suppression and cell mortality
40. Cancer cell cycles
41. ARF)ICDKN2B (p15) gene inactivation in malignant gliomas
42. ARF, participates in a regulatory feedback loop with p53 and MDM2
43. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas
44. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas
45. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
46. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p
47. Subsets of glioblastoma multiforme defined by molecular genetic analysis
48. Expression of p16INK4a/p16α and p19ARF/p16 β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
49. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies
50. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
51. INK4a genes in oligodendrogliomas
52. INK4a genes in human esophageal squamous cell carcinoma
53. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
54. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis